Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease has FDA Clinical Hold Lifted

(24/7 MARKET NEWS) – Fulcrum Therapeutics, Inc. (NASDAQ: FULC) stated, this morning, that the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease (SCD).

Fulcrum Therapeutics is trading at 5.03, up $1.11 (+28.32%), on 172.19K premarket shares traded.

Its 52-week range is $2.25 to $15.00. Great chart and it’s cleared its recent resistance, It has some resistance between here and the low $6 level, then a gap to the $12 level,

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist